fenofibrate has been researched along with eicosapentaenoic acid ethyl ester in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hotta, O; Ieiri, N; Taguma, Y | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
2 other study(ies) available for fenofibrate and eicosapentaenoic acid ethyl ester
| Article | Year |
|---|---|
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Glomerulus; Lipids; Lipoproteins; Male; Microscopy, Electron; Nephrotic Syndrome; Niceritrol; Pedigree; Probucol | 2003 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |